Allergy Therapeutics plc
("Allergy Therapeutics" or the "Company")
Director/PDMR Shareholding
24 October 2018 - Allergy Therapeutics (AIM:AGY), the fully integrated specialty pharmaceutical company specialising in allergy vaccines, announces that Manuel Llobet, Chief Executive Officer and Nick Wykeman, Chief Financial Officer, have today purchased 50,000 and 150,000 ordinary shares, respectively, of 0.1 pence each in the Company ("Ordinary Shares"), at a price of 17.5 pence per Ordinary Share. Furthermore, Peter Jensen, Non-Executive Chairman, has today purchased 20,000 Ordinary Shares at a price of 18 pence per Ordinary Share. Following the dealings, the interests of Manuel Llobet, Nick Wykeman and Peter Jensen in the issued share capital of the Company are set out below:
| Director | Shareholding | % of issued share capital
|
| Manuel Llobet | 3,325,000 | 0.52 |
| Nick Wykeman | 300,000 | 0.05 |
| Peter Jensen | 170,000 | 0.03 |
The notification below, made in accordance with the requirements of the EU Market Abuse Regulation, provides further detail.
Notification and public disclosure of transactions by persons discharging managerial responsibilities and/or persons closely associated with them:
| 1 | Details of the person discharging managerial responsibilities/person closely associated | |||||
| a) | Name
| Manuel Llobet | ||||
| 2 | Reason for the notification | |||||
|
|
| Chief Executive Officer, Director | ||||
| b) | Initial notification/Amendment
| Initial Notification | ||||
| 3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||
| a) | Name | Allergy Therapeutics plc | ||||
| b) | LEI | 213800PQ7AHK7KGVOE23 | ||||
| 4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||
| a) | Description of the financial instrument, type of instrument
Identification code | 0.1p ordinary shares
GB00B02LCQ05 | ||||
| b) | Nature of the transaction
| Purchase of Ordinary Shares | ||||
| c) | Price(s) and volume(s)
|
| ||||
| d) | Aggregated information
|
| ||||
| e) | Date of the transaction
| 23 October 2018 | ||||
| f) | Place of the transaction
| London Stock Exchange - AIM | ||||
| 1 | Details of the person discharging managerial responsibilities/person closely associated | |||||
| a) | Name
| Nick Wykeman | ||||
| 2 | Reason for the notification | |||||
|
|
| Chief Financial Officer, Director | ||||
| b) | Initial notification/Amendment
| Initial Notification | ||||
| 3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||
| a) | Name | Allergy Therapeutics plc | ||||
| b) | LEI | 213800PQ7AHK7KGVOE23 | ||||
| 4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||
| a) | Description of the financial instrument, type of instrument
Identification code | 0.1p ordinary shares
GB00B02LCQ05 | ||||
| b) | Nature of the transaction
| Purchase of Ordinary Shares | ||||
| c) | Price(s) and volume(s)
|
| ||||
| d) | Aggregated information
|
| ||||
| e) | Date of the transaction
| 23 October 2018 | ||||
| f) | Place of the transaction
| London Stock Exchange - AIM | ||||
| 1 | Details of the person discharging managerial responsibilities/person closely associated | |||||
| a) | Name
| Peter Jensen | ||||
| 2 | Reason for the notification | |||||
|
|
| Non-Executive Chairman, Director | ||||
| b) | Initial notification/Amendment
| Initial Notification | ||||
| 3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||
| a) | Name | Allergy Therapeutics plc | ||||
| b) | LEI | 213800PQ7AHK7KGVOE23 | ||||
| 4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||
| a) | Description of the financial instrument, type of instrument
Identification code | 0.1p ordinary shares
GB00B02LCQ05 | ||||
| b) | Nature of the transaction
| Purchase of Ordinary Shares | ||||
| c) | Price(s) and volume(s)
|
| ||||
| d) | Aggregated information
|
| ||||
| e) | Date of the transaction
| 23 October 2018 | ||||
| f) | Place of the transaction
| London Stock Exchange - AIM | ||||
- ENDS -
For further information, please contact:
Allergy Therapeutics
+44 (0) 1903 845 820
Manuel Llobet, Chief Executive Officer
Nick Wykeman, Chief Financial Officer
Panmure Gordon
+44 (0) 20 7886 2500
Freddy Crossley / Emma Earl, Corporate Finance
Erik Anderson, Corporate Broking
Consilium Strategic Communications
+44 20 3709 5700
Mary-Jane Elliott / David Daley / Nicholas Brown / Olivia Manser
Notes for editors:
About Allergy Therapeutics
Allergy Therapeutics is an international commercial biotechnology group focussed on the treatment and diagnosis of allergic disorders, including immunotherapy vaccines that have the potential to cure disease. The Group sells proprietary and third-party products from its subsidiaries in nine major European countries and via distribution agreements in an additional fourteen countries. Its broad pipeline of products in clinical development include vaccines for grass, tree and house dust mite, and peanut allergy vaccine in pre-clinical development. Adjuvant systems to boost performance of vaccines outside allergy are also in development.
Formed in 1999 out of Smith Kline Beecham, Allergy Therapeutics is headquartered in Worthing, UK with more than 11,000m2 of state-of-the-art MHRA-approved manufacturing facilities and laboratories. The Group, which has achieved 10% compound annual growth since formation, employs c.500 employees and is listed on the London Stock Exchange (AIM:AGY). For more information, please see www.allergytherapeutics.com.